Transscleral diffusion of ethacrynic acid and sodium fluorescein

Molecular Vision

Volumn 13, Issue , 2007, Pages 243-251

  Lin, Cheng Wen ^a   Wang, Yong ^a   Challa, Pratap ^b   Epstein, David L ^b   Yuan, Fan ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; ETACRYNIC ACID; FLUORESCEIN SODIUM;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL DAMAGE; CELL VIABILITY; CHOROID; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG BINDING; DRUG DIFFUSION; DRUG TRANSPORT; EX VIVO STUDY; GLAUCOMA; HYDROPHILICITY; LOW TEMPERATURE; MATHEMATICAL MODEL; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCLERA; SIMULATION; SWINE; THICKNESS;

ANIMALS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; CHOROID; DIFFUSION; ENZYMES; ETHACRYNIC ACID; FLUORESCEIN; FLUORESCENT DYES; HISTOLOGICAL TECHNIQUES; MODELS, BIOLOGICAL; OSMOLAR CONCENTRATION; SCLERA; SWINE; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33847301369     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol 2002; 133:S1-10.
2. Epstein DL, Roberts BC, Skinner LL. Nonsulfhydryl-reactive phenoxyacetic acids increase aqueous humor outflow facility. Invest Ophthalmol Vis Sci 1997; 38:1526-34.
3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-13; discussion829-30.
4. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol 1963; 69:783-801.
5. Ethier CR, Johnson M, Ruberti J. Ocular biomechanics and biotransport. Annu Rev Biomed Eng 2004; 6:249-73.
6. Johnson M. 'What controls aqueous humour outflow resistance?'. Exp Eye Res 2006; 82:545-57.
7. Tingey DP, Schroeder A, Epstein MP, Epstein DL. Effects of topical ethacrynic acid adducts on intraocular pressure in rabbits and monkeys. Arch Ophthalmol 1992; 110:699-702.
8. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006; 3:275-87.
9. Krol A, Maresca J, Dewhirst MW, Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res 1999; 59:4136-41.
10. Krol A, Dewhirst MW, Yuan F. Effects of cell damage and glycosaminoglycan degradation on available extravascular space of different dextrans in a rat fibrosarcoma. Int J Hyperthermia 2003; 19:154-64.
11. Zhang XY, Luck J, Dewhirst MW, Yuan F. Interstitial hydraulic conductivity in a fibrosarcoma. Am J Physiol Heart Circ Physiol 2000; 279:H2726-34.
12. Yamamoto K, Masubuchi Y, Narimatsu S, Kobayashi S, Horie T. Toxicity of ethacrynic acid in isolated rat hepatocytes. Toxicol In Vitro 2002; 16:151-8.
13. Jiang J, Geroski DH, Edelhauser HF, Prausnitz MR. Measurement and prediction of lateral diffusion within human sclera. Invest Ophthalmol Vis Sci 2006; 47:3011-6.
14. Nagataki S, Matsunaga I. Binding of fluorescein monoglucuronide to human serum albumin. Invest Ophthalmol Vis Sci 1985; 26:1175-8.
15. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J Biomed Mater Res 1997; 37:401-12.
16. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 1998; 87:1479-88.
17. Adams MC, Davis J. Kinetics of fluorescein decay and its application as a geothermal tracer. Geothermics 1991; 20:53-66.
18. Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992; 52:4157-67.
19. Beyer KH, Baer JE, Michaelson JK, Russo HF. Renotropic characteristics of ethacrynic acid: a phenoxyacetic saluretic-diuretic agent. J Pharmacol Exp Ther 1965; 147:1-22.
20. el Tayar N, Tsai RS, Testa B, Carrupt PA, Leo A. Partitioning of solutes in different solvent systems: the contribution of hydrogen-bonding capacity and polarity. J Pharm Sci 1991; 80:590-8.
21. Adamson RH, Huxley VH, Curry FE. Single capillary permeability to proteins having similar size but different charge. Am J Physiol 1988; 254:H304-12.
22. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol 1998; 8:164-75.
23. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000; 82:1513-8.
24. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, Kim I, Delori FC, Adamis AP. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41:1181-5.
25. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci 2006; 47:4513-22.
26. Mora P, Eperon S, Felt-Baeyens O, Gurny R, Sagodira S, Breton P, Guex-Crosier Y. Trans-scleral diffusion of triamcinolone acetonide. Curr Eye Res 2005; 30:355-61.
27. Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2006; 82:479-87.
28. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995; 36:1893-903.
29. Boubriak OA, Urban JP, Akhtar S, Meek KM, Bron AJ. The effect of hydration and matrix composition on solute diffusion in rabbit sclera. Exp Eye Res 2000; 71:503-14.
30. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci 1999; 40:3054-8.
31. Aihara M, Lindsey JD, Weinreb RN. Enhanced FGF-2 movement through human sclera after exposure to latanoprost. Invest Ophthalmol Vis Sci 2001; 42:2554-9.
32. Kim JW, Lindsey JD, Wang N, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 2001; 42:1514-21.
33. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001; 52:37-48.
34. Wang Y, Challa P, Epstein DL, Yuan F. Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. Biomaterials 2004; 25:4279-85.
35. Gilger BC, Salmon JH, Wilkie DA, Cruysberg LP, Kim J, Hayat M, Kim H, Kim S, Yuan P, Lee SS, Harrington SM, Murray PR, Edelhauser HF, Csaky KG, Robinson MR. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci 2006; 47:2596-605.